cas 245056-66-0|| where to buy N-(4-Chloropyridin-2-yl)acetamide

Nom du produit:N-(4-Chloropyridin-2-yl)acetamide

IUPAC Name:N-(4-chloropyridin-2-yl)acetamide

Unité d'emballage	Stock disponible	Prix($)
CM171450-1g	in stock	ũư
CM171450-5g	in stock	ȐǜȺ
CM171450-10g	in stock	ŵƿƿ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 245056-66-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:245056-66-0; Formule moléculaire:C7H7ClN2O; Point de fusion:-; Code SMILES:CC(NC1=NC=CC(Cl)=C1)=O; Densité:

: Numéro de catalogue:CM171450; Poids moléculaire:170.6; Point d'ébullition:356°C at 760 mmHg; N° Mdl:MFCD03394624; Stockage:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Tasurgratinib; Eisai announced that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor ‘TASFYGO® Tablets 35mg’ (tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. In Japan, it has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW), and the marketing authorization application was submitted in December 2023. TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.